Job title: Chief Scientific Officer
Thierry has 20 years’ experience in the biotechnology sector having managed drug discovery and drug development programs for small molecules, gene therapies, and regenerative cell-based therapies. Earlier in his career, as Scientific Project Leader in drug discovery programs for motor neuron disorders and subsequently as Head of CNS Pharmacology at Trophos, Thierry played a key role in the identification and preclinical development of olesoxime, the company’s lead compound which proved to be active in a phase 3 clinical trial for Spinal Muscular Atrophy. After Trophos’ acquisition by Roche, he became the Director of Preclinical Development at the Biotherapies Institute for Rare Diseases in Evry (France) where he conducted development strategies for advanced therapy medicinal products for various indications, including retinitis pigmentosa. He joined Eyevensys in 2017 to develop the company portfolio. Thierry is a graduate from ENS Lyon and holds a Ph.D in Microbiology and Virology from Paris VI University.
Panel Discussion: Discussing the Future of Gene Therapy Delivery 10:00 am
It is evident that effective vector design to target cells both more effectively and safely is a vital aspect of creating a successful gene therapy platform. Delivery to the eye specifically brings unique challenges, and therefore choosing the right vector to deliver the cargo will be central to any ophthalmic program. This panel discussion will…Read more
day: Day One
Beyond AAV: Realizing the Potential of Non-Viral Vectors 9:00 am
• Developing non-viral vectors to minimize immune response and re-dose as needed • Effectively targeting cells using non-viral and minimally invasive delivery approaches • Delivering larger genetic material to target cells • Extending the benefits of gene therapy to more common diseasesRead more
day: Day One